SEATTLE--(BUSINESS WIRE)--Archon Biosciences, a biotechnology company pioneering computationally designed Antibody Cages (AbCs) to unlock powerful therapeutic targets beyond the reach of existing modalities, today announced its emergence from stealth with $20 million in seed financing. The financing was led by Madrona Ventures with participation from DUMAC Inc., Sahsen Ventures, WRF Capital, Pack Ventures, Alexandria Venture Investments and Cornucopian Capital..

西雅图--（商业新闻短讯）--Archon Biosciences是一家生物技术公司，开创了计算设计的抗体笼（AbCs），以解锁现有模式无法实现的强大治疗目标，今天宣布其从隐形中崛起，获得2000万美元的种子融资。融资由Madrona Ventures牵头，DUMAC Inc.、Sahsen Ventures、WRF Capital、Pack Ventures、Alexandria Ventures Investments和Cornucopian Capital参与。。

AbCs are a completely novel class of biologic composed of antibodies combined with a boundless set of AI-generated protein structures that have never existed in nature. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold standard in drug development..

ABC是一类全新的生物制剂，由抗体与无限的AI产生的蛋白质结构组成，这些蛋白质结构在自然界中从未存在过。对AbC结构的精确控制提供了调节它们在体内分布的能力，并以高特异性和高效力参与其细胞靶标，以建立药物开发的新金标准。。

“There are many high-profile cases where we understand not only a target’s biology but also why past attempts to drug the target have failed in the clinic. These key disease levers are at our fingertips, but we lack the tools to safely and effectively engage them,” said James Lazarovits, Ph.D., co-founder and chief executive officer.

联合创始人兼首席执行官詹姆斯·拉扎罗维茨（JamesLazarovits）博士说：“在许多备受关注的病例中，我们不仅了解目标的生物学特性，而且还了解为什么过去对目标进行药物治疗的尝试在临床上失败了。这些关键的疾病杠杆就在我们的指尖上，但我们缺乏安全有效的工具。”。

“Our transformational Antibody Cage technology is designed to drug many of these challenging targets underlying diseases of paramount urgency and create better treatment options for patients. With the support of our investors, we have developed a proprietary protein design platform coupled with rapid in-house manufacturing and testing to revolutionize how biologics are developed.”.

“我们的转化性抗体笼技术旨在治疗许多具有挑战性的潜在疾病，为患者创造更好的治疗选择。在投资者的支持下，我们开发了一个专有的蛋白质设计平台，结合快速的内部制造和测试，彻底改变生物制剂的开发方式。”。

Archon’s platform leverages AI-driven advances in computational protein design that were recognized earlier this month by the 2024 Nobel Prize in Chemistry for their ability to create novel proteins with desired functions. One of this year’s three laureates, University of Washington (UW) Professor of Biochemistry and Howard Hughes Medical Institute investigator Dr.

Archon的平台利用了人工智能驱动的计算蛋白质设计的进步，这些进步在本月早些时候被2024年诺贝尔化学奖认可，因为它们能够创造具有所需功能的新型蛋白质。今年的三位获奖者之一，华盛顿大学（UW）生物化学教授和霍华德·休斯医学研究所研究员Dr。

David Baker, Ph.D., leads the Institute for Protein Design (IPD), where he co-invented the Archon platform alongside co-founders and former UW Research Faculty and IPD Translational Investigators Dr. Lazarovits and Dr. George Ueda, Ph.D..

David Baker博士领导蛋白质设计研究所（IPD），与联合创始人、前UW研究院和IPD转化研究者Lazarovits博士和George Ueda博士共同发明了Archon平台。。

Archon directly applies generative protein design to drug development by not only conceiving but readily manufacturing new molecular entities for preclinical investigation. AbC design combines off-the-shelf antibodies and computationally designed binding proteins that self-assemble into exquisitely precise and geometrically defined nanostructures.

Archon通过不仅构思而且容易制造用于临床前研究的新分子实体，直接将生成性蛋白质设计应用于药物开发。AbC设计结合了现成的抗体和计算设计的结合蛋白，这些结合蛋白可以自组装成精确且几何定义的纳米结构。

Based on their unique geometries, AbCs behave in the body and interact with their targets differently than conventional biologics, with much greater control over functional properties such as target engagement and biodistribution..

基于其独特的几何形状，ABC在体内的行为及其与靶标的相互作用与传统生物制剂不同，对靶标参与和生物分布等功能特性的控制更大。。

During manufacturing, antibodies are incorporated into AbCs without the need to modify sequence or alter established production processes. As a result, AbC assembly is massively parallelizable, easily automated and retains the industry-proven binding affinity and specificity of antibodies while enabling rapid exploration of a new geometric design and application space..

在制造过程中，抗体被掺入ABC中，而不需要修改序列或改变已建立的生产过程。因此，AbC组装可以大规模并行化，易于自动化，并保留了业界证明的抗体结合亲和力和特异性，同时可以快速探索新的几何设计和应用空间。。

The Archon team has more than a decade of experience creating designed proteins for therapeutic applications. Dr. Ueda, chief technology officer, spent over 10 years at the IPD under the directorship of Dr. Baker and was one of the first scientists to show the therapeutic utility of designed proteins through his work with computationally designed vaccines and signaling proteins..

Archon团队拥有十多年的经验，为治疗应用创造了设计的蛋白质。首席技术官上田博士（Ueda Dr.Ueda）在贝克博士（Dr.Baker）的领导下在IPD工作了10多年，是首批通过计算设计的疫苗和信号蛋白的工作展示设计蛋白质治疗效用的科学家之一。。

The translational academic group of Drs. Ueda and Lazarovits received initial grants totaling over $7 million from IPD’s Translational Program, Washington Research Foundation, The National Institutes of Health, The Department of Defense and the Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH) to develop the AbC platform and early preclinical candidates.

由Ueda博士和Lazarovits博士组成的转化学术小组从IPD的转化项目、华盛顿研究基金会、国立卫生研究院、国防部和华盛顿创业研究评估和商业化中心（WE-REACH）获得了总计700多万美元的初始赠款，以开发AbC平台和早期临床前候选人。

The group later licensed the AbC technology from UW..

该集团后来从UW获得了AbC技术的许可。。

“AbCs are a revolutionary approach to antibody therapeutics that creates immediately actionable engineering solutions to intractable drug development challenges,” said Chris Picardo, Partner at Madrona Ventures, and Board Member of Archon Biosciences. “James and George have assembled a team of world-class scientists and pharmaceutical industry veterans that is able to create new preclinical molecules with extraordinary speed and accuracy.

Madrona Ventures合伙人兼Archon Biosciences董事会成员克里斯·皮卡多（ChrisPicardo）表示：“ABC是一种革命性的抗体治疗方法，可以为棘手的药物开发挑战创建立即可行的工程解决方案。”。“詹姆斯和乔治组建了一支由世界级科学家和制药行业资深人士组成的团队，能够以非凡的速度和准确性创造出新的临床前分子。

We’re excited to partner with them at the forefront of generative protein design and realize the myriad of possibilities to engage currently undruggable targets and pathways to improve human health.”.

我们很高兴与他们合作，站在生成蛋白质设计的最前沿，并认识到参与目前不可治疗的目标和途径以改善人类健康的无数可能性。”。

About Archon Biosciences

关于Archon Biosciences

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. Archon directly applies generative protein design to rapidly manufacture Antibody Cages (AbCs), a new class of biologics with unique potency and differentiated biodistribution.

Archon是一家生物技术公司，开发计算设计的蛋白质，以解锁现有模式无法实现的强大治疗目标，并更好地治疗疾病。Archon直接应用生成蛋白质设计来快速制造抗体笼（ABC），这是一类具有独特效力和差异化生物分布的新型生物制剂。

AbCs integrate the unparalleled binding affinity and specificity of antibodies into novel self-assembling nanostructures designed to overcome the most difficult challenges in drug development. For more information visit www.archon.bio.

ABC将抗体无与伦比的结合亲和力和特异性整合到新型自组装纳米结构中，旨在克服药物开发中最困难的挑战。有关更多信息，请访问www.archon.bio。